Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2020
Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2020
SUMMARY
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 6 molecules. The latest report Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2020, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron%li%and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others. The molecules developed by companies in Pre-Registration, Phase III and Phase I stages are 2, 2 and 2 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
Furthermore, this report also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 6 molecules. The latest report Transmembrane Prolyl 4 Hydroxylase - Pipeline Review, H2 2020, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Prolyl 4 hydroxylases (P4H) are iron%li%and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others. The molecules developed by companies in Pre-Registration, Phase III and Phase I stages are 2, 2 and 2 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
Furthermore, this report also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
- The report reviews Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
Bayer AG
FibroGen Inc
GlaxoSmithKline Plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDO-3055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enarodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0463518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
Featured News & Press Releases
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Jun 29, 2020: Japan grants approval for GSK's Duvroq to treat CKD-related anaemia
Jun 08, 2020: Roxadustat demonstrates non-inferiority to darbepoetin in phase 3 dolomites study of anemia in non-dialysis-dependent adult patients with chronic kidney disease
Jun 08, 2020: FibroGen announces new roxadustat data presented at 2020 ERA-EDTA Virtual Congress
May 20, 2020: European Medicines Agency accepts Astellas' Marketing Authorization Application for Roxadustat
Apr 20, 2020: FibroGen reports UK Court Ruling
Feb 11, 2020: FibroGen announces U.S. FDA acceptance of new drug application for Roxadustat for the treatment of Anemia of Chronic Kidney Disease
Jan 31, 2020: Astellas and FibroGen seek Japanese approval for Evrenzo
Dec 23, 2019: FibroGen submits New Drug Application to the U.S. FDA for Roxadustat in patients with anemia of chronic kidney disease
Dec 02, 2019: FibroGen announces Roxadustat inclusion in China’s National Reimbursement Drug List
Nov 29, 2019: JT Files New Drug Application of Enarodustat(JTZ-951),for the treatment of Anemia Associated with CKD in Japan
Nov 08, 2019: Roxadustat phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease versus comparators
Nov 08, 2019: AstraZeneca reports positive Phase III data for roxadustat
Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase III data at the American Society of Nephrology Kidney Week 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Figures
Introduction
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Companies Involved in Therapeutics Development
Bayer AG
FibroGen Inc
GlaxoSmithKline Plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Drug Profiles
daprodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DDO-3055 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enarodustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
molidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0463518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Product Development Milestones
Featured News & Press Releases
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Aug 26, 2020: Kyowa Kirin announces the approval of Duvroq in Japan by GSK for patients with renal anemia due to chronic kidney disease
Jun 29, 2020: Japan grants approval for GSK's Duvroq to treat CKD-related anaemia
Jun 08, 2020: Roxadustat demonstrates non-inferiority to darbepoetin in phase 3 dolomites study of anemia in non-dialysis-dependent adult patients with chronic kidney disease
Jun 08, 2020: FibroGen announces new roxadustat data presented at 2020 ERA-EDTA Virtual Congress
May 20, 2020: European Medicines Agency accepts Astellas' Marketing Authorization Application for Roxadustat
Apr 20, 2020: FibroGen reports UK Court Ruling
Feb 11, 2020: FibroGen announces U.S. FDA acceptance of new drug application for Roxadustat for the treatment of Anemia of Chronic Kidney Disease
Jan 31, 2020: Astellas and FibroGen seek Japanese approval for Evrenzo
Dec 23, 2019: FibroGen submits New Drug Application to the U.S. FDA for Roxadustat in patients with anemia of chronic kidney disease
Dec 02, 2019: FibroGen announces Roxadustat inclusion in China’s National Reimbursement Drug List
Nov 29, 2019: JT Files New Drug Application of Enarodustat(JTZ-951),for the treatment of Anemia Associated with CKD in Japan
Nov 08, 2019: Roxadustat phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease versus comparators
Nov 08, 2019: AstraZeneca reports positive Phase III data for roxadustat
Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase III data at the American Society of Nephrology Kidney Week 2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by FibroGen Inc, H2 2020
Pipeline by GlaxoSmithKline Plc, H2 2020
Pipeline by Japan Tobacco Inc, H2 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by FibroGen Inc, H2 2020
Pipeline by GlaxoSmithKline Plc, H2 2020
Pipeline by Japan Tobacco Inc, H2 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
